5th June 2001
Cancer Research Ventures Ltd, a London based independent technology transfer company specialised in oncology announces today that it has signed an exclusive license agreement with Epigenomics AG, Berlin, Germany.
Epigenomics focuses on developing diagnostics and therapeutics based on the study of DNA methylation patterns of the genome. They have extensive expertise, proprietary intellectual property and know how in this field.
Dr Guldberg funded by the Danish Cancer Society has invented a useful, patent protected high speed methylation detection assay. It is hoped that it will lead the way to the use on a routine basis of diagnostic tests based on DNA methylation.
Epigenomics will develop and commercialise this novel methylation detection assay. Most recent research has shown that DNA methylation patterns correlate with various disease states and in particular with cancer. Identification of the aberrantly methylated genes will certainly lead to the development of novel diagnostics and therapeutics.
CRV provides commercialisation and intellectual property management services to cancer research institutes world-wide. CRV’s goal is to bridge the gap between exciting new research, in this case funded by the DCS at the Institute of Cancer Biology and its timely development by the best suited commercial partner.
Notes to Editors:
Cancer Research Ventures
Ltd (CRV) is a technology transfer and development company
established by The Cancer Research Campaign in the UK to
provide technology transfer services to cancer researchers
on a world wide basis. CRV, and its forerunner CRCT, have
been providing these services to UK researchers since 1987
and have recently expanded the business into Europe and
now further afield through its affiliate company Biotech
Research Ventures in Singapore. CRV has been instrumental
in establishing a number of successful biotech companies
in the UK.
Danish Cancer Society: The Danish Cancer Society is a voluntary non-profit association with a mission to fight and prevent cancer, it runs its own research department in Aarhus and Copenhagen, including biological, epidemiological, clinical trial and psychosocial projects. The DCS also supports specific research projects elsewhere in Denmark. As a corner stone of its biological research DCS’ Institute of Cancer Biology focuses in apoptosis, tumour cell biology (in particular tumour immunology), tumour endocrinology, molecular cancer biology and cell cycle. The DCS pays for about half of all Danish cancer research.
|
